| | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C23H30N4O3 |
| Molar mass | 410.518 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Protonitazene is a benzimidazole derivative with potent opioid effects which has been sold over the internet as a designer drug since 2019, and has been identified in various European countries, as well as Canada, the US and Australia. [1] It has been linked to numerous cases of drug overdose, and is a Schedule I drug in the US. [2] [3] [4] [5] [6]
It was developed by a Swiss pharmaceutical company in the 1950s as an alternative to morphine, but was never adopted due to severe side effects. [7]
Protonitazen er et syntetisk opioid som ble utviklet av et sveitsisk legemiddelselskap på 50-tallet. Det var ment som et alternativ til morfin, men på grunn av alvorlige bivirkninger ble stoffet aldri tatt i bruk.[Protonitazen is a synthetic opioid that was developed by a Swiss pharmaceutical company in the 50s. It was intended as an alternative to morphine, but due to severe side effects, the drug was never used.]